Pages that link to "Q57266592"

The following pages link to Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer (Q57266592):

Displaying 35 items.

• Breast ductal lavage for biomarker assessment in high risk women: rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placebo (Q21261269) (← links)
• Breast cancer subtypes and previously established genetic risk factors: a bayesian approach (Q28397311) (← links)
• Identification of inherited genetic variations influencing prognosis in early-onset breast cancer (Q28943279) (← links)
• Retrospective analysis of clinicopathological characteristics and family history data of early-onset breast cancer: a single-institutional study of Hungarian patients (Q30633035) (← links)
• Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer (Q33739351) (← links)
• The prevalence of BRCA1/2 mutations of triple-negative breast cancer patients in Xinjiang multiple ethnic region of China (Q33826713) (← links)
• Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells (Q34152071) (← links)
• BRCA2 Mutations and Triple-Negative Breast Cancer (Q34293001) (← links)
• Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer (Q34460831) (← links)
• Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer (Q34996647) (← links)
• Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer (Q35000673) (← links)
• Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia (Q35155449) (← links)
• Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: single center experience (Q35214479) (← links)
• Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population. (Q35722508) (← links)
• BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years (Q35832295) (← links)
• Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA. (Q36087198) (← links)
• High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients (Q36110709) (← links)
• Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis (Q36420170) (← links)
• High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors (Q36793398) (← links)
• Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality. (Q36800313) (← links)
• Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores (Q37710182) (← links)
• Triple-negative breast cancer: investigating potential molecular therapeutic target (Q38259322) (← links)
• Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers. (Q38262476) (← links)
• Hereditary breast cancer syndromes and genetic testing (Q38266306) (← links)
• Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women. (Q38691342) (← links)
• Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. (Q39375196) (← links)
• Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study (Q44358008) (← links)
• Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer (Q44429695) (← links)
• Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer (Q51293206) (← links)
• Prevalence and Spectrum of BRCA1/2 Germline Mutations in Women with Breast Cancer in China Based on Next-Generation Sequencing. (Q52571638) (← links)
• Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation. (Q54514641) (← links)
• Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. (Q54522260) (← links)
• Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia (Q64055786) (← links)
• Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition (Q90430590) (← links)
• Differential Profile of BRCA1 vs. BRCA2 Mutated Families: A Characterization of the Main Differences and Similarities in Patients (Q93059332) (← links)